RedHill's Opaganib Emerges as Potential Ebola Treatment Amid Rising Outbreak
Event summary
- RedHill Biopharma is advancing Opaganib as a potential treatment for Ebola virus disease (EVD) amid a rising outbreak with 3,221 confirmed cases and 1,407 deaths as of July 28, 2026.
- Opaganib demonstrated a 70.2% mortality reduction in severe COVID-19 patients when combined with remdesivir, suggesting potential efficacy against EVD.
- Preclinical studies funded by USAMRIID showed Opaganib's inhibition of EVD in human macrophages and increased survival rates in animal models.
- RedHill is in discussions with the African Medicines Agency, Ugandan Ministry of Health, and other partners to finalize development steps for Opaganib.
The big picture
RedHill Biopharma's push to position Opaganib as an Ebola treatment comes at a critical time, with the current outbreak highlighting the need for effective and easily administrable therapies. The drug's host-directed mechanism of action and oral formulation could address gaps in existing treatments, particularly in regions with limited healthcare infrastructure. The strategic partnerships being formed underscore the urgency and potential market opportunity for Opaganib in global infectious disease preparedness.
What we're watching
- Regulatory Approval
- Whether Opaganib will gain acceptance into Ebola virus disease control programs and demonstrate efficacy in clinical settings.
- Partnership Success
- The pace at which RedHill finalizes partnerships with African Medicines Agency and other health authorities to expedite Opaganib's development.
- Clinical Validation
- How the preclinical and clinical data for Opaganib will translate into real-world effectiveness against EVD during the current outbreak.
Related topics